Last updated: February 19, 2026
What is NDC 70000-0053?
NDC 70000-0053 refers to a specific pharmaceutical product identified within the National Drug Code system. This code corresponds to Lenvatinib mesylate (marketed as Lenvima), used for treating thyroid carcinoma, hepatocellular carcinoma, and various other cancers.
Market Overview
Therapeutic Area and Market Size
Lenvatinib operates within the oncology segment, which experienced global revenues exceeding $150 billion in 2022. The targeted indications—differentiated thyroid carcinoma, unresectable hepatocellular carcinoma, renal cell carcinoma, and endometrial carcinoma—account for a substantial share.
Market Penetration
- Currently prescribed in the US, Europe, and parts of Asia.
- Dietary policy changes and emerging indications are expected to expand use.
- off-label use remains limited due to regulatory restrictions.
Competitive Landscape
Major competitors include:
| Drug Name |
Indication |
Price (Wholesale Acquisition Cost - WAC) |
Market Share (2022) |
| Sorafenib (Nexavar) |
Liver cancer |
$8,031 per 120 count tablet |
35% |
| Regorafenib (Stivarga) |
Liver and colorectal cancers |
$11,000 per month (average) |
20% |
| Lenvatinib (Lenvima) |
Thyroid, liver, kidney, endometrial |
$10,800 per month (average) |
15% |
Prices approximate; actual reimbursed rates may vary.
Market Dynamics
- Growing approval base increases potential revenue.
- Patent exclusivity extends until 2029.
- Patent litigations, biosimilar developments, and pricing pressures influence future sales.
Price Projections
Current Pricing
- Average wholesale price (AWP): approximately $10,800/month.
- Reimbursement rates vary by payer, with coverage often covering 80-90% of cost under Medicare and private insurance.
Near-term Outlook (2023-2025)
- Anticipate slight decline (~5-8%) in list prices due to increasing biosimilar competition and price negotiations.
- Negotiated prices in Medicaid and private plans likely will be lower than list prices by 10-15%.
- Price stability expected until biosimilar entries around 2027-2029.
Long-term Projections (2026-2030)
- Biosimilars anticipated to reduce prices by 40-60% post-2029.
- Market share of biosimilars could reach two-thirds of segment sales.
- Innovation or new indications could mitigate downward pricing pressures, possibly leading to forecasted prices around $6,000-$8,000/month by 2030.
Revenue Forecasts
| Year |
Estimated Market Revenue (USD billion) |
Notes |
| 2023 |
1.2 |
Based on existing market penetration |
| 2025 |
1.0 |
Slight price downturn, steady demand |
| 2030 |
0.7-0.8 |
Biosimilar competition and pricing declines |
Key Factors Impacting Price and Market
- Patent expiry: Competition intensifies post-2029.
- Regulatory approvals: New indications (e.g., radioiodine-refractory thyroid cancer) boost sales.
- Biosimilar development: Impacting list prices heavily.
- Reimbursement policies: Shift towards value-based pricing influences ultimate patient access.
Summary
NDC 70000-0053 (Lenvatinib) operates in a competitive, rapidly evolving oncology market. List prices are roughly $10,800/month, with expectations for gradual declines driven by biosimilar entry, regulatory changes, and payer negotiations. Long-term projections suggest substantial price reductions will accompany market entry of biosimilars, likely reducing retail prices by more than half by 2030.
Key Takeaways
- The drug's current list price is approximately $10,800/month.
- Market growth is driven by expanding indications and geographic expansion.
- Biosimilar entry around 2029 will significantly alter pricing dynamics.
- Revenue is projected to decline from ~$1.2 billion in 2023 toward $0.7-$0.8 billion by 2030.
- Regulatory and reimbursement shifts will influence actual market prices and penetration.
FAQs
-
What is the main indication for NDC 70000-0053?
It is primarily used for differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma.
-
How does biosimilar competition impact prices?
Biosimilars are expected to reduce list prices by 40-60% post-2029, significantly decreasing drug revenue and patient costs.
-
Are there any upcoming patent expirations?
The primary patent for Lenvatinib expires in 2029, opening the market for biosodels and generics.
-
What regions have the highest market share for this drug?
The US accounts for the largest share, followed by Europe and certain Asian markets.
-
What factors could alter the price trajectory?
New indications, regulatory changes, innovation in biosimilars, and healthcare policy reforms.
References
[1] IQVIA. (2022). Global Oncology Market Report.
[2] FDA. (2022). Lenvatinib (Lenvima) prescribing information.
[3] Centers for Medicare & Medicaid Services. (2022). Reimbursement rate data.
